Abstract
Thrombocytopenia is a common disease in the clinic. In severe cases, it can be life-threatening. Thrombopoietin receptor agonists (TPO-RA) can effectively increase platelet counts in patients with thrombocytopenia and reduce blood transfusion dependence. As the second-generation TPO-RA, eltrombopag (EP) has been approved for thrombocytopenia caused by chronic immune thrombocytopenic purpura (cITP), severe aplastic anemia(SAA), and infection of chronic hepatitis C (HCV). This article reviews the progress of the application of EP in thrombocytopenia. Key words: Receptors, thrombopoietin; Thrombocytopenia; Hepatitis C; Anemia, aplastic; Eltrombopag
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
